



## **Nkarta to Participate at Upcoming Investor Conferences**

February 10, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

### **SVB Leerink 11<sup>th</sup> Annual Global Healthcare Conference**

February 17, 2022

1:40 p.m. ET – fireside chat presentation

### **Cowen 42<sup>nd</sup> Annual Health Care Conference**

March 7, 2022

10:30 a.m. ET – leukemias panel discussion

### **Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference**

March 16, 2022

10:00 a.m. ET – presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately four weeks.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Greg Mann

Nkarta, Inc.

[gmann@nkartatx.com](mailto:gmann@nkartatx.com)